股本结构
单位：万股
| 公告日期 | 2025-11-07 | 2025-11-07 | 2025-11-07 | 2025-11-07 | 2025-11-07 | 2025-08-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 8232.44 | 8231.62 | 8075.34 | 8016.48 | 8014.92 | 7998.90 |
| 普通股本 | 8232.44 | 8231.62 | 8075.34 | 8016.48 | 8014.92 | 7998.90 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-07 | 2025-11-03 | 2025-10-22 | 2025-10-07 | 2025-09-30 | 2025-07-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-07 | 8232.44 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-07 | 8231.62 | 未披露 | 定期报告 | 2025-11-03 |
| 2025-11-07 | 8075.34 | 未披露 | 定期报告 | 2025-10-22 |
| 2025-11-07 | 8016.48 | 未披露 | 定期报告 | 2025-10-07 |
| 2025-11-07 | 8014.92 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Exercise of stock options
Common stock issued for vested restricted stock units
|
2025-09-30 |
| 2025-08-08 | 7998.90 | 未披露 | 定期报告 | 2025-07-31 |
| 2025-08-08 | 7991.92 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Common stock issued for vested restricted stock units
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2025-06-30 |
| 2025-05-12 | 7971.76 | 未披露 | 定期报告 | 2025-05-01 |
| 2025-04-28 | 7967.92 | 未披露 | 定期报告 | 2025-04-10 |
| 2025-05-12 | 7966.99 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Exercise of stock options
Common stock issued for vested restricted stock units
Issuance of common stock and accompanying pre-funded warrants in a follow-on offering, net of issuance costs
Issuance of common stock pursuant to ATM offering, net of issuance costs
|
2025-03-31 |
| 2025-02-28 | 7962.01 | 未披露 | 定期报告 | 2025-02-14 |
| 2025-01-29 | 7513.26 | 未披露 |
更多>>
Common stock offered 5,333,420 shares of common stock by the company
|
2025-01-30 |
| 2025-02-28 | 7238.30 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to a follow-on offering, net of issuance costs
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to ATM offering, net of issuance costs
Exercise of stock options
|
2024-12-31 |
| 2024-11-08 | 6979.91 | 未披露 | 定期报告 | 2024-10-31 |
| 2024-11-08 | 6961.46 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of stock options
Common stock issued for vested restricted stock units
|
2024-09-30 |
| 2024-08-09 | 6943.08 | 未披露 | 定期报告 | 2024-08-02 |
| 2024-08-09 | 6920.57 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock pursuant to ESPP purchases
Exercise of stock options
Common stock issued for vested restricted stock units
|
2024-06-30 |
| 2024-04-26 | 6915.10 | 未披露 | 定期报告 | 2024-04-10 |
| 2024-05-10 | 6914.84 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to a follow-on offering, net of issuance costs
Exercise of stock options
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
|
2024-03-31 |
| 2024-03-06 | 6729.75 | 未披露 |
更多>>
Common stock offered 11,000,000 shares by the company
|
2024-03-08 |
| 2024-02-29 | 5629.75 | 未披露 | 定期报告 | 2024-02-23 |
| 2024-02-29 | 5575.44 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Exercise of stock options
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
Issuance of common stock pursuant to a direct offering, net of issuance costs
|
2023-12-31 |
| 2023-11-13 | 5570.98 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-13 | 5568.10 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Common stock issued for vested restricted stock units
Exercise of stock options
|
2023-09-30 |
| 2023-08-11 | 5560.22 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-11 | 5554.80 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock pursuant to a direct offering, net of issuance costs
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2023-06-30 |
| 2023-05-17 | 5532.55 | 未披露 |
更多>>
Common stock offered by the company 5,238,500 shares
|
2023-05-19 |
| 2023-05-15 | 5008.70 | 未披露 | 定期报告 | 2023-05-11 |
| 2023-04-28 | 4842.27 | 未披露 | 定期报告 | 2023-04-24 |
| 2023-04-28 | 4727.56 | 未披露 | 定期报告 | 2023-04-06 |
| 2023-05-15 | 4697.91 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of stock options
Common stock issued for Vested restricted stock units
|
2023-03-31 |
| 2023-03-17 | 4697.10 | 未披露 | 定期报告 | 2023-03-14 |
| 2023-03-17 | 4686.52 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs
Exercise of stock options
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $13,800
|
2022-12-31 |
| 2022-11-04 | 4676.32 | 未披露 | 定期报告 | 2022-10-28 |
| 2022-11-04 | 4665.75 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of stock options
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $13,800
|
2022-09-30 |
| 2022-09-15 | 4641.65 | 未披露 |
更多>>
1.Common Stock offered 7,692,308 shares by the company
2.1,153,846 shares of Common Stock which was exercised in full on September 15, 2022
|
2022-09-19 |
| 2022-08-05 | 3757.14 | 未披露 | 定期报告 | 2022-07-29 |
| 2022-08-05 | 3757.03 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs
Issuance of common stock pursuant to ESPP purchases
|
2022-06-30 |
| 2022-05-06 | 3502.29 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-02-25 | 3501.29 | 未披露 | 定期报告 | 2022-02-15 |
| 2022-02-25 | 3490.07 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2021-12-31 |
| 2021-11-12 | 3488.83 | 未披露 | 定期报告 | 2021-11-09 |
| 2021-11-12 | 3487.53 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
|
2021-09-30 |
| 2021-08-13 | 3486.19 | 未披露 | 定期报告 | 2021-08-08 |
| 2021-08-13 | 3484.08 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2021-06-30 |
| 2021-05-13 | 3482.61 | 未披露 | 定期报告 | 2021-05-07 |
| 2021-04-27 | 3482.03 | 未披露 | 定期报告 | 2021-04-05 |
| 2021-05-13 | 3477.03 | 未披露 |
更多>>
From December 31, 2020 to March 10, 2021
Exercise of stock options
|
2021-03-10 |
| 2021-03-16 | 3474.16 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $906
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2020-12-31 |
| 2020-11-12 | 3472.18 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-11-12 | 3472.07 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock upon closing of secondary public offering, net of issuance costs and underwriting fees of $906
Exercise of stock options
|
2020-09-30 |
| 2020-08-12 | 3470.08 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-07-10 | 3389.94 | 未披露 |
更多>>
1.Common stock offered by the company 5,228,166 shares
2.The number of shares of common stock to be outstanding after this offering is based on 28,671,222 shares of common stock outstanding as of March 31, 2020.
|
2020-07-10 |
| 2020-08-12 | 2868.37 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2020-06-30 |
| 2020-05-13 | 2867.36 | 未披露 | 定期报告 | 2020-05-08 |
| 2020-07-06 | 2867.12 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Exercise of stock options
|
2020-03-31 |
| 2020-03-16 | 2860.79 | 未披露 | 定期报告 | 2020-03-06 |
| 2020-03-16 | 2856.78 | 未披露 |
更多>>
From December 31, 2018 To December 31, 2019
Conversion of convertible preferred stock into common stock upon closing of public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $10,348
Issuance of restricted common stock upon early exercise of stock options
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
|
2019-12-31 |
| 2019-11-12 | 2855.87 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of restricted common stock upon early exercise of stock options
|
2019-09-30 |
| 2019-08-12 | 2855.54 | 未披露 |
更多>>
From December 31, 2018 To June 30, 2019
Conversion of convertible preferred stock into common stock upon closing of initial public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $10,348
Issuance of restricted common stock upon early exercise of stock options
Exercise of stock options
|
2019-06-30 |
| 2019-06-20 | 2704.51 | 未披露 |
更多>>
1.Common stock offered 5,750,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 21,295,122 shares of our common stock outstanding as of March 31, 2019
3.a one-for-3.07418 reverse stock split of our common stock effected on June 6, 2019
|
2019-06-20 |
| 2019-05-24 | 73.47 | 未披露 | 定期报告 | 2019-03-31 |
From June 30, 2025 to September 30, 2025
Exercise of stock options
Common stock issued for vested restricted stock units
From March 31, 2025 to June 30, 2025
Common stock issued for vested restricted stock units
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
From December 31, 2024 to March 31, 2025
Exercise of stock options
Common stock issued for vested restricted stock units
Issuance of common stock and accompanying pre-funded warrants in a follow-on offering, net of issuance costs
Issuance of common stock pursuant to ATM offering, net of issuance costs
Common stock offered 5,333,420 shares of common stock by the company
From December 31, 2023 to December 31, 2024
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to a follow-on offering, net of issuance costs
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to ATM offering, net of issuance costs
Exercise of stock options
From June 30, 2024 to September 30, 2024
Exercise of stock options
Common stock issued for vested restricted stock units
From March 31, 2024 to June 30, 2024
Issuance of common stock pursuant to ESPP purchases
Exercise of stock options
Common stock issued for vested restricted stock units
From December 31, 2023 to March 31, 2024
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to a follow-on offering, net of issuance costs
Exercise of stock options
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
Common stock offered 11,000,000 shares by the company
From December 31, 2022 to December 31, 2023
Exercise of stock options
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
Issuance of common stock pursuant to a direct offering, net of issuance costs
From June 30, 2023 to September 30, 2023
Common stock issued for vested restricted stock units
Exercise of stock options
From March 31, 2023 to June 30, 2023
Issuance of common stock pursuant to a direct offering, net of issuance costs
Common stock issued for vested restricted stock units
Issuance of common stock pursuant to At-The-Market ("ATM") offering, net of issuance costs
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
Common stock offered by the company 5,238,500 shares
From December 31, 2022 to March 31, 2023
Exercise of stock options
Common stock issued for Vested restricted stock units
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to ESPP purchases
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs
Exercise of stock options
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $13,800
From June 30, 2022 to September 30, 2022
Exercise of stock options
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $13,800
1.Common Stock offered 7,692,308 shares by the company
2.1,153,846 shares of Common Stock which was exercised in full on September 15, 2022
From March 31, 2022 to June 30, 2022
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs
Issuance of common stock pursuant to ESPP purchases
From December 31, 2020 to December 31, 2021
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
From June 30, 2021 to September 30, 2021
Exercise of stock options
From March 31, 2021 to June 30, 2021
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
From December 31, 2020 to March 10, 2021
Exercise of stock options
From December 31, 2019 to December 31, 2020
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees of $906
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
From June 30, 2020 to September 30, 2020
Issuance of common stock upon closing of secondary public offering, net of issuance costs and underwriting fees of $906
Exercise of stock options
1.Common stock offered by the company 5,228,166 shares
2.The number of shares of common stock to be outstanding after this offering is based on 28,671,222 shares of common stock outstanding as of March 31, 2020.
From March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
From December 31, 2019 to March 31, 2020
Exercise of stock options
From December 31, 2018 To December 31, 2019
Conversion of convertible preferred stock into common stock upon closing of public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $10,348
Issuance of restricted common stock upon early exercise of stock options
Exercise of stock options
Issuance of common stock pursuant to ESPP purchases
from June 30, 2019 to September 30, 2019
Issuance of restricted common stock upon early exercise of stock options
From December 31, 2018 To June 30, 2019
Conversion of convertible preferred stock into common stock upon closing of initial public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $10,348
Issuance of restricted common stock upon early exercise of stock options
Exercise of stock options
1.Common stock offered 5,750,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 21,295,122 shares of our common stock outstanding as of March 31, 2019
3.a one-for-3.07418 reverse stock split of our common stock effected on June 6, 2019